Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

News Industry News

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

November 21, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

The Case for TAVR

Presenter: Michael A. Borger, Vinod H. Thourani, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

Case #3: Transseptal Puncture for Left Atrial Appendage Closure

Presenter: Samir R. Kapadia, Horst Sievert, Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

Presenter: James S. Gammie, James B. Hermiller Jr., Brian K. Whisenant

October 30, 2016

Presentation TVT 2016

Transseptal Walk-through: How to Do It The Maneuvers

Presenter: Brian K. Whisenant

June 17, 2016

Presentation TVT 2016

MitraClip Complications: Frequency, Avoidance Strategies, and Management

Presenter: Brian K. Whisenant

June 16, 2016

Presentation TVT 2016

Clip Placement Strategies and Knowing When to Stop (or Not)

Presenter: Brian K. Whisenant

June 16, 2016

Presentation Scripps 2016

Putting It All Together: Warfarin, NOAC or LAA Closure?

Presenter: Brian K. Whisenant

February 04, 2016

Presentation Scripps 2016

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

Presenter: Brian Whisenant

February 04, 2016

Presentation Scripps 2016

LAA Closure for Stroke Prevention: Rationale and Identifying the Patient Who Might Benefit

Presenter: Brian K. Whisenant

February 03, 2016

Presentation Scripps 2016

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

Presenter: Brian K. Whisenant

February 03, 2016

Presentation TCT 2015

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Presenter: Vinod H. Thourani, Brian K. Whisenant, Alec S. Vahanian

October 14, 2015

Presentation TCT 2015

Debate: No, the Bar Is Too High MitraClip/Annuloplasty Approaches Will Always Be Safer and Nearly as Effective!

Presenter: Vinod H. Thourani, Brian K. Whisenant, Ted E. Feldman

October 14, 2015

Presentation TCT 2015

Debate: Yes, Transcatheter MV Replacement Will Become Standard of Care for Secondary MR!

Presenter: Vinod H. Thourani, Brian K. Whisenant, Shmuel Banai

October 14, 2015

Presentation TCT 2015

Case 2: Transseptal Puncture for Left Atrial Appendage Closure

Presenter: Ted E. Feldman, Samir R. Kapadia, Saibal Kar, Brian K. Whisenant

October 13, 2015

Presentation TCT 2015

Coherex WaveCrest and the WAVECREST 2 Randomized Trial

Presenter: Brij Maini, Horst Sievert, Brian K. Whisenant

October 12, 2015

Presentation TCT 2015

Debate: Is Pericardial LAA Exclusion Better Than Endocardial LAA Closure? No, Intracardiac LAA Closure Is Proven, and the Pericardial Approach Has Major Concerns!

Presenter: Maurice Buchbinder, Brian K. Whisenant, Josep Rodés-Cabau

October 12, 2015

Advertisement

Two Differing Blood Clot Prevention Medications Used During Heart Procedure Are Both Safe and Effective for Patients, New Study Finds

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

The Case for TAVR

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? Yes Minimize Bleeding Risk and Improve Long-term Outcomes!

Case #3: Transseptal Puncture for Left Atrial Appendage Closure

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

Transseptal Walk-through: How to Do It The Maneuvers

MitraClip Complications: Frequency, Avoidance Strategies, and Management

Clip Placement Strategies and Knowing When to Stop (or Not)

Putting It All Together: Warfarin, NOAC or LAA Closure?

LAA Closure for Prevention of AF Stroke: Clinical Trial Data

LAA Closure for Stroke Prevention: Rationale and Identifying the Patient Who Might Benefit

LAA Closure for Stroke Prevention: Novel and Next Generation Devices

My Rosy Prophecy: What Will the Specialty of Mitral Valve Therapeutics Look Like in 10 Years?

Debate: No, the Bar Is Too High MitraClip/Annuloplasty Approaches Will Always Be Safer and Nearly as Effective!

Debate: Yes, Transcatheter MV Replacement Will Become Standard of Care for Secondary MR!

Case 2: Transseptal Puncture for Left Atrial Appendage Closure

Coherex WaveCrest and the WAVECREST 2 Randomized Trial

Debate: Is Pericardial LAA Exclusion Better Than Endocardial LAA Closure? No, Intracardiac LAA Closure Is Proven, and the Pericardial Approach Has Major Concerns!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content